Gut microbiome homeostasis and the future of probiotics in cancer immunotherapy

Frontiers in Immunology

Immunology

Sunil Martin¹  Ankita Singh¹  Sharon Grace Alexander¹ 

[1]Synthetic Immunology Laboratory, Cancer Research Division, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, Kerala, India

关键词: gut microbiome;    cancer immunotherapy;    check point blockade inhibitors;    stem cell transplantation;    CAR T cells;   

DOI  :  10.3389/fimmu.2023.1114499

 received in 2022-12-06, accepted in 2023-04-17,  发布年份 2023

来源: Frontiers

【 摘 要 】

The gut microbiome has an impact on cancer immune surveillance and immunotherapy, with recent studies showing categorical differences between immunotherapy-sensitive and immunotherapy-resistant cancer patient cohorts. Although probiotics are traditionally being supplemented to promote treatments or sustain therapeutic benefits; the FDA has not approved any for use with immunotherapy. The first step in developing probiotics for immunotherapy is identifying helpful or harmful bacteria down to the strain level. The gut microbiome’s heterogeneity before and during treatment is also being investigated to determine microbial strains that are important for immunotherapy. Moreover, Dietary fiber intake, prebiotic supplementation and fecal microbiota transplantation (FMT) were found to enhance intratumoral CD8+ T cell to T-reg ratio in the clinics. The possibility of probiotic immunotherapy as a “living adjuvant” to CAR treatment and checkpoint blockade resistance is actively being investigated.

【 授权许可】

Unknown   
Copyright © 2023 Singh, Alexander and Martin